Wednesday, July 8, 2026

pharma · Irritable Bowel Syndrome With Constipation · Chronic Constipation · IRWD

IRONWOOD PHARMACEUTICALS

IRONWOOD PHARMACEUTICALS clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

100 Summer Street, Boston, MA 02110, US HQ
1998 Founded
262 Employees
Public company Type
IRWD · NYSE Ticker
Company details
Status
Public
HQ
100 Summer Street, Boston, MA 02110, US
Founded
1998
Employees
262
Programs
33
Drugs
11
Patents
45
Intelligence · Clinical Programs

IRONWOOD PHARMACEUTICALS projects

3 ClinicalTrials.gov programs sponsored by IRONWOOD PHARMACEUTICALS.

IRONWOOD PHARMACEUTICALS has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Lesinurad

    IRONWOOD PHARMACEUTICALS INC

    Gout

    approved small molecule terminated

    1 trial
  2. Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome Characterized by Constipation

    approved small molecule completed

    2 trials
  3. Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    approved small molecule completed

    3 trials

Frequently asked questions

How many clinical projects does IRONWOOD PHARMACEUTICALS have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.